Newsroom
Sorted by: Latest
-
Consilio Expands eDiscovery in Australia & New Zealand Through Integration of elaw
SYDNEY--(BUSINESS WIRE)--Consilio, a global leader in technology-enabled legal services & AI solutions, announced the integration of elaw, an Australian eDiscovery provider....
-
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising an...
-
KBRA Comments on Blue Owl Capital Corporation II's Asset Sales
NEW YORK--(BUSINESS WIRE)--On February 17, 2026, Blue Owl Capital Corp. II (“OBDC II” or “the company”) (KBRA Issuer/ Senior Unsecured Debt ratings of BBB+/Stable outlook) filed a Form 8-K disclosing entry into loan sale agreements totaling $600 million at 99.7% of par including unfunded commitments. The transactions are expected to generate approximately $538 million of proceeds after fees, which the company intends to use to repay secured debt and to distribute approximately 30% of total net...
-
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a post...
-
Empire State Realty Trust Achieves WELL Health-Safety Leadership Award for Second Consecutive Year and Healthy Building Catalyst Award
NEW YORK--(BUSINESS WIRE)--Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that it received the 2025 International WELL Building Institute (IWBI) WELL Health Safety Leadership award, for its prioritization of building occupant health and well-being, and the 2025 Healthy Building Catalyst award, for outstanding public promotion of health and well-being practices. ESRT achieved the WELL Health-Safety Rating across 100% of its portfolio in each year of participation since 2020. “ESRT'...
-
Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...
-
Klaviyo Executives to Participate in Morgan Stanley Technology, Media & Telecom Conference
BOSTON--(BUSINESS WIRE)--Klaviyo (NYSE: KVYO), the autonomous B2C CRM, today announced that Andrew Bialecki, Co-Founder and Co-CEO, Chano Fernandez, Co-CEO, and Amanda Whalen, CFO, will participate in a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference on Wednesday, March 4, 2026 at 5:35 p.m. ET / 2:35 p.m. PT. Live webcasts and replays will be available on Klaviyo’s investor relations website at https://investors.klaviyo.com/. About Klaviyo Klaviyo (CLAY-vee-oh) is...
-
Better and Framework Ventures Announce Strategic Partnership to Enable Deployment of $500MM into Better via Sky’s Stablecoin Ecosystem
NEW YORK--(BUSINESS WIRE)--Better Home & Finance Holding Company (NASDAQ: BETR), the AI-native mortgage and home equity finance company, and Framework Ventures, a leading SF-based venture capital firm with a background in the decentralized finance ecosystem, today announced they have agreed to launch a strategic partnership that aims to provide $500MM in credit via integration of Better into the Sky stablecoin ecosystem as the home finance “Star” within the Sky ecosystem. Sky allocates capi...
-
PicPay Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
SÃO PAULO--(BUSINESS WIRE)--PicPay (NASDAQ: PICS) announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, March 18, 2026, after market close. The Company will host a conference call and webcast to discuss its results on the same day at 6:00 PM Brasília Time (5:00 PM Eastern Standard Time). Participants may register for and access the conference call using the link found here. A live webcast and replay of the conference cal...
-
Westlake Corporation Appoints New Directors to its Board
HOUSTON--(BUSINESS WIRE)--Westlake Corporation (NYSE: WLK) announced that Mr. Bhavesh V. “Bob” Patel and Mr. Jean-Marc Gilson, the President and Chief Executive Officer of the Company, have been elected to the company’s board of directors, effective February 20, 2026. “We are very pleased to welcome Bob to our board,” said Westlake Corporation Executive Chairman Albert Chao. “He brings a wealth of experience and in-depth knowledge of the chemicals and building materials industries and adds to t...